Exacerbating factors in patients with IgA nephropathy.
D000328:Adult; D003182:Complement C5 / Q000032:analysis; D003186:Complement C9 / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D005455:Fluorescent Antibody Technique; D005922:Glomerulonephritis, IGA / Q000150:complications* / Q000276:immunology / Q000473:pathology; D006023:Glycoproteins / Q000032:analysis; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007071:Immunoglobulin A, Secretory / Q000032:analysis; D007678:Kidney Glomerulus / Q000032:analysis / Q000276:immunology / Q000473:pathology; D009061:Mouth Mucosa / Q000276:immunology; D010614:Pharynx / Q000276:immunology; D012141:Respiratory Tract Infections / Q000150:complications; D012635:Secretory Component / Q000032:analysis; D019096:Vitronectin
D003182:Complement C5; D003186:Complement C9; D006023:Glycoproteins; D007070:Immunoglobulin A; D007071:Immunoglobulin A, Secretory; D012635:Secretory Component; D019096:Vitronectin; D005340:Fibrinogen